中外医疗
中外醫療
중외의료
CHINA FOREIGN MEDICAL TREATMENT
2015年
13期
136-137
,共2页
纳洛酮%慢阻肺并Ⅱ型呼吸衰竭%临床疗效%安全性
納洛酮%慢阻肺併Ⅱ型呼吸衰竭%臨床療效%安全性
납락동%만조폐병Ⅱ형호흡쇠갈%림상료효%안전성
Naloxone%Chronic obstructive pulmonary disease and respiratory failure%Clinical efficacy%Safety
目的：对应用纳洛酮治疗慢阻肺并Ⅱ型呼吸衰竭的临床疗效与用药安全性进行评价。方法随机选取2011年1月-2014年10月该院收治的72例慢阻肺并II型呼吸衰竭患者为研究对象，根据随机数字表法分为两组。两组患者均给予常规治疗，观察组在此基础上给予纳洛酮，比较两组患者治疗前后的血气分析四项指标变化、临床疗效及不良反应发生率。结果两组治疗前血气分析指标pH、PaO2、PaCO2及SaO2差异无统计学意义(P>0.05)，治疗后两组血气分析指标均有所好转，但观察组各项指标均显著优于对照组(P<0.05)。对照组治疗有效率为75.5%，观察组治疗有效率为94.4%，组间比较观察组明显高于对照组，差异有统计学意义(P<0.05)。两组均有患者出现恶心、呕吐等现象，无心律失常、抽搐等不良反应。其中对照组不良反应发生率为11.1%，观察组为16.7%，组间比较差异无统计学意义(P>0.05)。结论纳洛酮在治疗慢阻肺并Ⅱ型呼吸衰竭中临床疗效显著，能有效解除呼吸抑制，促进通气，改善机体缺氧与CO2潴留，且安全性高，可在临床上进行推广应用。
目的：對應用納洛酮治療慢阻肺併Ⅱ型呼吸衰竭的臨床療效與用藥安全性進行評價。方法隨機選取2011年1月-2014年10月該院收治的72例慢阻肺併II型呼吸衰竭患者為研究對象，根據隨機數字錶法分為兩組。兩組患者均給予常規治療，觀察組在此基礎上給予納洛酮，比較兩組患者治療前後的血氣分析四項指標變化、臨床療效及不良反應髮生率。結果兩組治療前血氣分析指標pH、PaO2、PaCO2及SaO2差異無統計學意義(P>0.05)，治療後兩組血氣分析指標均有所好轉，但觀察組各項指標均顯著優于對照組(P<0.05)。對照組治療有效率為75.5%，觀察組治療有效率為94.4%，組間比較觀察組明顯高于對照組，差異有統計學意義(P<0.05)。兩組均有患者齣現噁心、嘔吐等現象，無心律失常、抽搐等不良反應。其中對照組不良反應髮生率為11.1%，觀察組為16.7%，組間比較差異無統計學意義(P>0.05)。結論納洛酮在治療慢阻肺併Ⅱ型呼吸衰竭中臨床療效顯著，能有效解除呼吸抑製，促進通氣，改善機體缺氧與CO2潴留，且安全性高，可在臨床上進行推廣應用。
목적：대응용납락동치료만조폐병Ⅱ형호흡쇠갈적림상료효여용약안전성진행평개。방법수궤선취2011년1월-2014년10월해원수치적72례만조폐병II형호흡쇠갈환자위연구대상，근거수궤수자표법분위량조。량조환자균급여상규치료，관찰조재차기출상급여납락동，비교량조환자치료전후적혈기분석사항지표변화、림상료효급불량반응발생솔。결과량조치료전혈기분석지표pH、PaO2、PaCO2급SaO2차이무통계학의의(P>0.05)，치료후량조혈기분석지표균유소호전，단관찰조각항지표균현저우우대조조(P<0.05)。대조조치료유효솔위75.5%，관찰조치료유효솔위94.4%，조간비교관찰조명현고우대조조，차이유통계학의의(P<0.05)。량조균유환자출현악심、구토등현상，무심률실상、추휵등불량반응。기중대조조불량반응발생솔위11.1%，관찰조위16.7%，조간비교차이무통계학의의(P>0.05)。결론납락동재치료만조폐병Ⅱ형호흡쇠갈중림상료효현저，능유효해제호흡억제，촉진통기，개선궤체결양여CO2저류，차안전성고，가재림상상진행추엄응용。
Objective To explore the clinical efficacy and drug safety evaluation of application of naloxone in treating chronic ob-structive pulmonary disease and respiratory failure. Methods 72 cases of COPD patients with type II respiratory failure as the ob-ject of study were selected in our hospital from January,2011 to October,2014, two groups of patients were given conventional treatment. On the basis of the observation group received naloxone, blood gas before and after treatment in two groups were com-pared by analysis of four indicators of changes, clinical effect and adverse reaction incidence rate. Results There were no signifi-cant index analysis of pH, PaO2, PaCO2 and SaO2 difference between the two groups before treatment, blood gas (P>0.05), two groups of blood gas analysis after treatment indicators have improved, but the observation group indicators were significantly better than the control group (P<0.05). Effective rate of treatment in the control group was 75.5%, the effective rate of treatment in obser-vation group was 94.4%, the observation group was significantly higher than the control group, the difference has statistical signifi-cance (P<0.05). Two groups of patients have nausea, vomiting and other phenomena, no adverse reaction of arrhythmia, twitch. The incidence of adverse reaction in the control group was 11.1% and the observation group was16.7%, no significant difference be-tween two groups (P>0.05). Conclusion Naloxone in the treatment of COPD and type II respiratory failure have clinical curative effect, which can effectively relieve respiratory inhibition, promote ventilation, improve hypoxia and CO2 retention, and high safety, can be widely applied in clinical practice.
